Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.

Background: Randomized clinical trials with the aim of evaluating the cardiovascular risks associated with glucagon-like peptide 1 (GLP-1) receptor agonists, lixisenatide, liraglutide, semaglutide, and exenatide, have been conducted. They showed different results among the agents, but the reason has not been explained.

Objective: To evaluate the cardiovascular risks associated with GLP-1 receptor agonists by using an alternative measure to the hazard ratio.

Evaluation of digital linear tomosynthesis imaging of the temporomandibular joint: initial clinical experience and evaluation.

Objectives: This study was performed to evaluate the potential clinical application of digital linear tomosynthesis systems in imaging of the temporomandibular joint (TMJ).

Methods: A volumetric X-ray digital linear tomosynthesis system (Sonialvision Safire; Shimadzu Co., Kyoto, Japan) was used for TMJ imaging.